A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.
Astrazeneca Plc Ord Shs $0.25 is listed on the London Stock Exchange trading with ticker code AZN.L, and is part of the Medicine and Biotech Research sector. It has a market capitalisation of £7,740,056m, with approximately 1,267m shares in issue.
Astrazeneca Plc, officially known as Astrazeneca Plc Ord Shs $0.25 was formed in June of 1992, making the company twenty seven years old. The company filed its latest accounts on 31st December 2014, showing a turnover of approximately 17.16 billion GBX with gross profits of 13.32 billion, or 10.5134 per issued share, and a pre-tax profit margin of 4.77%. Astrazeneca Plc currently has 12 directors, and has had 37 previous directors over the last 27 years. In the last set of accounts produced by Kpmg Llp, the company showed 4.13 billion paid in salaries to the 57,500 staff (average wage of 72 thousand), with the directors receiving an average 383 thousand each. In the accounts filed in 2014, the company paid 0 in dividends.
Astrazeneca Plc is in the Medicine and Biotech Research sector.
|Royal Dutch Shell Plc 'B' (RDSB.L)|
|Summit Therapeutics Plc (SUMM.L)|
|Lloyds Bank (LLOY.L)|
|Hikma Pharmaceuticals Plc (HIK.L)|
|Shares in Issue||1,267m|
|52 Week High||0.00|
|52 Week Low||0.00|